Increased Benefits of Noninvasive Diagnostics
Endometriosis Therapeutics without Infertility and Menopausal Effects
Estimates of the prevalence of endometriosis vary from 5%-20%, with a prevalence as high as 35 percent in women with severe menstrual cramps. A study in Germany found the prevalence of diagnosed endometriosis to be roughly 8.1 percent, increasing to 12.8 percent for women aged 35-44. 2 One thing is clear from disparate estimates: Illness affects millions of women globally. Endometriosis is estrogen-dependent and therapy generally involves suppression of the action of estrogen, with resulting effects on fertility and side effects like those of melancholy. There is clearly a need for therapeutics to have a more positive risk-benefit balance.
The prevalence of bacterial vaginosis from the USA is approximately 29.2% among women aged 14-49. There are effective therapeutics but recurrence rates may be as high as 80 percent. 3 Bacterial vaginosis represents a significant health problem since it raises risks for pelvic inflammatory disease, sexually transmitted infections such as HIV, postsurgical infection after gynecologic procedures, spontaneous abortion, preterm labor, and low birth weight. Therefore, women need a therapeutic for bacterial vaginosis which not only cures bacterial vaginosis in the near term but also prevents recurrence.
Bacterial Vaginosis Therapeutics with Longer Durable Efficacy
Noninvasive diagnostics for women’s health conditions, particularly conditions like ovarian and cervical cancer that are often diagnosed when it’s too late for effective treatment, represent a significant unmet need in women’s health and an opportunity for the diagnostics industry. There is also a need for improved diagnostics in other regions. For instance, girls are vocal in their displeasure with the experience of mammography and there’s a demand for non-invasive prenatal diagnostics for a greater array of hereditary health conditions.
Female Sexual Dysfunction encompasses Female Sexual Interest/Arousal Disorder, Female Orgasmic Disorder, and Genito-Pelvic Pain/Penetration Disorder. Even though therapeutics for female sexual dysfunction remains controversial in certain circles, there were an estimated 4.1 million off-label prescriptions written in 2011 for testosterone as a treatment for women who seek help with this sign. 1 This strongly suggests that a market opportunity exists for a treatment that shows efficacy and has a more favorable side effect profile than dosing a female individual having a male hormone. FDA approval of flibanserin (Addyi®) was an important milestone but early marketplace statistics suggest women unhappy with their sexual lives are still anticipating a landmark occasion to rival the 1998 introduction of sildenafil (Viagra®) for male sexual dysfunction.
Osteoporosis Therapeutics with a More Favorable Risk-Benefit Profile
Significant unmet medical needs profoundly affect the lives of hundreds of millions of girls worldwide. Women have more than their fair share of health care needs for an Assortment of reasons, for example:
While there has been considerable progress in therapeutics for osteoporosis, it is not rare for girls to discontinue treatment if side effects are difficult to tolerate. New therapeutics that tilt the balance in favor of treatment benefits and against dangers would find a vast and increasing market as the worldwide population ages.
Women’s health needs change substantially over the life cycle, from childhood and adolescence through the childbearing years and melancholy; this increases the challenge for medical researchers in addressing and understanding a diverse and evolving set of health issues. Several chronic diseases disproportionately affect women, such as type 2 diabetes, diabetes, lupus, multiple sclerosis, and depression. Because girls often live longer than men, they’re more likely to experience geriatric conditions like osteoarthritis and Alzheimer’s disease. Diagnosis of several women’s health conditions, such as prostate cancer, requires invasive processes that usually delay treatment and detection and also exacerbate outcomes. Therapeutics for a few common women’s health conditions are lacking in efficiency, durability, or tolerability.
More Effective Therapeutics for Female Sexual Dysfunction
Estimates of the prevalence of uterine fibroids differ from 5-21 percent, with speeds rising substantially for women aged 35-49, with prevalence >80% among African American women by age 50 and 70% among Caucasian women. 4 nearly all women are asymptomatic, and yet uterine fibroids will be the leading cause of hysterectomies in the United States. Current treatment options include oral contraceptives or progestins, levonorgestrel-releasing intrauterine system (LNG-IUS), and GnRH-agonists. Women would welcome enhanced interventions from the biopharma and medical device industries.
Looking Forward to New Women’s Health Products and Possibilities